Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|February 19, 1999
Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC)C Boni, L Savoldi, G Bisagni, et al.
BMC Cancer|September 28, 2011
Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TTEnke Baldini, Yannick Arlot-Bonnemains, Salvatore Sorrenti, et al.
Blood|January 1, 1997
Hemophilia and nonprogressing human immunodeficiency virus type 1 infectionE Vicenzi, P Bagnarelli, E Santagostino, et al.
World Neurosurgery|October 10, 2025
Perioperative Predictors of Recurrency in Chronic Subdural Hematoma: A Retrospective Analysis of 150 Consecutive CasesA Fratini, C Noya, S Santi, et al.
Brain Injury|November 16, 2020
Psychological status and role of caregivers in the neuro-rehabilitation of patients with severe Acquired Brain Injury (ABI)U Bivona, D Villalobos, M De Luca, et al.
International Journal of Oncology|May 3, 2011
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesisC Gridelli, G Ianniello, G Ambrosini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckP Bossi, R Miceli, L D Locati, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 20, 2019
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant studyV Guarneri, M V Dieci, G Bisagni, et al.
ESMO Real World Data and Digital Oncology|April 3, 2026
Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 studyM E Cazzaniga, V Cogliati, E Rossi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Pageof 13